The research report titled ‘Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 ? 2025’, available with Market Study Report, claims that worldwide non-invasive prenatal testing market is anticipated to account for USD 2.5 billion by the year 2025.
 

Rising prevalence of down syndrome in neonatal babies, and shifting trend among women for having pregnancy at later age (more than 35 years) are primarily propelling the growth of global non-invasive prenatal testing market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1162034/
 

Notably, non-invasive prenatal testing (NPIT) do not pose any risk of miscarriage, which along with favorable reimbursement scenario, and individual preference for non-invasive techniques over invasive procedures are stimulating the market outlook.
 

Apart from highlighting the growth catalysts, the study document also enlists the bottlenecks and restraints arresting the industry expansion, and offer insights about tactics which can be leveraged to convert challenges into opportunities.
 

The business intelligence report examines the historical data for 2014-2017 and current business trends to predict the market size and remuneration over 2018-2025. It expounds on statistics such as NPIT test volume, and associated revenues generation.
 

As per test type, global non-invasive prenatal testing market is classified into veracity test, bambini test, prena test, IONA test, verifi test, NIFTY test, harmony test, materniT21 plus test, panorama test, and others.
 

Speaking of geographical realm, the report considers nations, namely Moldova, Armenia, Denmark, Poland, Turkey, Netherland, Belgium, Sweden, Switzerland, France Spain, Italy, Germany, Russia, New Zealand, Australia, Brazil, India, China, Japan, and United States, as the major growth avenues for industry partakers.
 

Global non-invasive prenatal testing industry players profiled in the report are NIPD Genetics, Yourgene Health plc (formerly Premaitha Health plc), LifeCodexx AG, Berry Genomics Co. Ltd., BGI Group, Quest Diagnostics, Natera Inc., Illumina Inc., Ariosa Diagnostics (acquired by Roche Holding AG), and Sequenom Laboratories (LabCorp).